What is the 13F Pro Quality Score for UNCY?

13F Pro ranks Unicycive Therapeutics, Inc. (UNCY) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View UNCY's current score at https://13fpro.ai/research/UNCY (free sign-up required for the full ranking).

Which hedge funds own the most UNCY stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of UNCY include Vivo Capital,, MILLENNIUM MANAGEMENT, Octagon Capital Advisors. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/UNCY as soon as new 13F filings post.

Where does 13F Pro source UNCY data?

All Unicycive Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Unicycive Therapeutics, Inc. files with the SEC under CIK 1766140. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is UNCY in?

Unicycive Therapeutics, Inc. (UNCY) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is UNCY research updated on 13F Pro?

UNCY's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Unicycive Therapeutics, Inc.(UNCY)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1766140 UNCY stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $1.0M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

UNCY Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Unicycive Therapeutics, Inc. (UNCY), a Healthcare sector company. UNCY is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $1.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), Unicycive Therapeutics, Inc. reports net income of $-12.8M, free cash flow of $-6.2M. Top institutional holders of UNCY by reported 13-F value include Vivo Capital,, MILLENNIUM MANAGEMENT, Octagon Capital Advisors, based on the most recent SEC filings. UNCY trades on the Nasdaq exchange and files with the SEC under CIK 1766140. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate UNCY daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Unicycive Therapeutics, Inc. directly from SEC EDGAR.

Net Income

Q1 2026

$-12.8M

Free Cash Flow

Q1 2026

$-6.2M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

—FY 2024

FY21 —FY22 $951.0KFY23 $675.0KFY24 —

Net Income

-20.2% YoY

$-36.7MFY 2024

FY21 $-10.0MFY22 $-18.1MFY23 $-30.5MFY24 $-36.7M

Operating Income

-54.6% YoY

$-32.1MFY 2024

FY21 $-9.0MFY22 $-18.1MFY23 $-20.8MFY24 $-32.1M

EPS (Diluted)

-341.4% YoY

$-5.65FY 2024

FY21 $-0.86FY22 $-1.20FY23 $-1.28FY24 $-5.65

Total Assets

+123.2% YoY

$31.7MFY 2024

FY21 $18.7MFY22 $2.8MFY23 $14.2MFY24 $31.7M

Op. Cash Flow

-56.3% YoY

$-28.6MFY 2024

FY21 $-5.8MFY22 $-15.7MFY23 $-18.3MFY24 $-28.6M

Metric	FY 2024	FY 2023	FY 2022	FY 2021	FY 2019
Revenue	—	$675.0K -29.0%	$951.0K	—	—
Net Income	$-36.7M -20.2%	$-30.5M -69.1%	$-18.1M -80.3%	$-10.0M	—
Operating Income	$-32.1M -54.6%	$-20.8M -15.1%	$-18.1M -101.1%	$-9.0M	—
EPS (Diluted)	$-5.65 -341.4%	$-1.28 -6.7%	$-1.20 -39.5%	$-0.86	—
Total Assets	$31.7M +123.2%	$14.2M +403.6%	$2.8M -85.0%	$18.7M	—
Operating Cash Flow	$-28.6M -56.3%	$-18.3M -16.8%	$-15.7M -171.4%	$-5.8M	—

AI Insight: UNCY Financial Trends

Unicycive remains pre-revenue with persistent operating cash burn of $6–9M per quarter, though equity has recovered sharply to $38M in Q1 2026 from a $28M deficit in Q3 2024.

• Revenue has been $0M or unreported every quarter from Q2 2024 through Q1 2026 — no commercial inflection yet.

• Operating cash outflow has ranged $6M–$9M per quarter consistently since Q2 2024, showing no meaningful burn-rate improvement.

• Equity swung from a $28M deficit in Q3 2024 to a positive $38M in Q1 2026, suggesting equity raises have shored up the balance sheet.

⚠ Equity dipped from $37M in Q3 2025 to $30M in Q4 2025 before recovering — monitor whether dilutive raises continue to sustain solvency.

⚠ With zero revenue and ~$7–8M quarterly cash burn, runway is entirely dependent on external financing; any funding gap is a critical risk.

AI Insight: UNCY Ratio Trends

Unicycive's profitability metrics are deeply negative and deteriorating, with ROE swinging from +20.2% in Q1 2025 to -194.3% by Q4 2025.

• ROE collapsed from +20.2% in Q1 2025 to -194.3% in Q4 2025, then partially recovered to -136.0% in Q1 2026.

• ROA turned sharply negative, falling from +8.2% in Q1 2025 to -86.0% in Q2 2025, remaining deeply negative at -79.6% in Q1 2026.

• ROIC worsened from -78.2% in Q3 2025 to -95.7% in Q4 2025, with only marginal improvement to -89.5% in Q1 2026.

⚠ Data is too sparse across OpMargin, NPM, and D/E to assess capital structure or operating efficiency trends.

⚠ The brief positive ROE/ROA spike in Q1 2025 warrants scrutiny — whether it reflects a one-off gain or a genuine inflection.

⚠ Sustained ROIC below -79% across available quarters signals ongoing capital destruction at a pre-revenue clinical-stage company.

Get alerted when UNCY's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Unicycive Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of UNCY

Vivo Capital, LLC
$11.8M1,789,916 sh
MILLENNIUM MANAGEMENT LLC
$9.2M1,399,348 sh
Octagon Capital Advisors LP
$6.6M1,000,000 sh
Nantahala Capital Management, LLC
$6.2M939,202 sh
VANGUARD CAPITAL MANAGEMENT LLC
$5.3M811,430 sh
GREAT POINT PARTNERS LLC
$5.2M796,558 sh
Logos Global Management LP
$3.1M473,563 sh
SUSQUEHANNA INTERNATIONAL GROUP, LLP
$2.1M324,500 sh
CITADEL ADVISORS LLC
$1.6M236,841 sh
Integral Health Asset Management, LLC
$1.5M225,000 sh

Fund	Value	Shares
Vivo Capital, LLC	$11.8M	1,789,916
MILLENNIUM MANAGEMENT LLC	$9.2M	1,399,348
Octagon Capital Advisors LP	$6.6M	1,000,000
Nantahala Capital Management, LLC	$6.2M	939,202
VANGUARD CAPITAL MANAGEMENT LLC	$5.3M	811,430
GREAT POINT PARTNERS LLC	$5.2M	796,558
Logos Global Management LP	$3.1M	473,563
SUSQUEHANNA INTERNATIONAL GROUP, LLP	$2.1M	324,500
CITADEL ADVISORS LLC	$1.6M	236,841
Integral Health Asset Management, LLC	$1.5M	225,000

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put UNCY on your watchlist

Track score changes the day Unicycive Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is UNCY a good stock to buy?

13F Pro's AI-powered analysis of Unicycive Therapeutics, Inc. (UNCY) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for UNCY are available on the UNCY stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own UNCY?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling UNCY. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Unicycive Therapeutics, Inc.'s investment landscape.